Patents by Inventor Mark Braughler

Mark Braughler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered Dendritic Cells and Uses for the Treatment of Cancer
    Publication number: 20170312315
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Application
    Filed: May 10, 2017
    Publication date: November 2, 2017
    Applicants: Intrexon Corporation, University of Pittsburgh-Of The Commonwealth System Of Higher Education
    Inventors: Mark BRAUGHLER, Prasanna Kumar, Walter J. Storkus, Hideho Okada
  • Engineered dendritic cells and uses for the treatment of cancer
    Patent number: 9675642
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: June 13, 2017
    Assignees: University Of Pittsburgh—Of The Commonwealth System Of Higher Education, Intrexon Corporation
    Inventors: J. Mark Braughler, Prasanna Kumar, Walter J Storkus, Hideho Okada
  • Engineered Dendritic Cells and Uses for the Treatment of Cancer
    Publication number: 20120114620
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Application
    Filed: September 1, 2011
    Publication date: May 10, 2012
    Applicant: Intrexon Corporation
    Inventors: J. Mark BRAUGHLER, Prasanna Kumar, Walter J. Storkus, Hideho Okada
  • Engineered Dendritic Cells and Uses for the Treatment of Cancer
    Publication number: 20090123441
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Application
    Filed: October 8, 2008
    Publication date: May 14, 2009
    Inventors: J. MARK BRAUGHLER, PRASANNA KUMAR, WALTER J. STORKUS, HIDEHO OKADA
  • Quantification and differentiation of tissue based upon quantitative image analysis
    Publication number: 20030048931
    Abstract: We disclose quantitative geometrical analysis enabling the measurement of several features of images of tissues including number, size, density of extracted hepatocyte nuclei, and other metrics. Automation of feature extraction creates a high throughput capability that enables analysis of histologically prepared tissue sections for accurate quantification of extracted features from tissues. Measurement results are input into a relational database where they can be statistically analyzed and compared across studies. As part of the integrated process, results are also imprinted on the images themselves to facilitate auditing of the results. The analysis is objective, fast, repeatable and accurate and provides an alternative or supplement to the subjective analysis of tissue slides by a pathologist.
    Type: Application
    Filed: March 25, 2002
    Publication date: March 13, 2003
    Inventors: Peter Johnson, Othman Abdulkarim, Michael Fuhrman, Mark Disilvestro, Ronald Stone, Mark Braughler
  • Use of high doses of derivatives of 6.alpha.-methylprednisolone for the acute treatment of stroke syndrome
    Patent number: 4554271
    Abstract: Use of water soluble 21-dibasic esters of 1-dehydro-6.alpha.-methylhydrocortisone for the acute treatment of stroke syndrome in humans.
    Type: Grant
    Filed: February 24, 1984
    Date of Patent: November 19, 1985
    Assignee: The Upjohn Company
    Inventors: J. Mark Braughler, Edward D. Hall